HUP0401091A2 - Atazanavir alkalmazása HIV-terápiában - Google Patents

Atazanavir alkalmazása HIV-terápiában

Info

Publication number
HUP0401091A2
HUP0401091A2 HU0401091A HUP0401091A HUP0401091A2 HU P0401091 A2 HUP0401091 A2 HU P0401091A2 HU 0401091 A HU0401091 A HU 0401091A HU P0401091 A HUP0401091 A HU P0401091A HU P0401091 A2 HUP0401091 A2 HU P0401091A2
Authority
HU
Hungary
Prior art keywords
atazanavir
therapy
hiv protease
cholesterol
hiv
Prior art date
Application number
HU0401091A
Other languages
English (en)
Inventor
Clifford M. Bechtold
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0401091A2 publication Critical patent/HUP0401091A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Az találmány szerint atazanavir (BMS-232632) alkalmazható HIV-fertőzéskezelésénél emelkedett plazma LDL-koleszterin és/vagy trigliceridszintek csökkentésére szolgáló gyógyszerkészítményekben olyanbetegeknél; akiknél egy előzetes HIV proteáz terápia következményekéntemelkedett plazma LDL-koleszterin és/vagy triglicerid szintekmutathatók ki. A terápiában az ártalmas HIV-proteáz inhibitor helyettatazanavir vagy az atazanavir és egy citokrom P450 monooxigenázzalmetabolizált HIV-proteáz inhibitor kombinációját tartalmazógyógyszerkészítmény alkalmazható. Ó
HU0401091A 2001-08-31 2002-08-21 Atazanavir alkalmazása HIV-terápiában HUP0401091A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31674501P 2001-08-31 2001-08-31
PCT/US2002/026675 WO2003020206A2 (en) 2001-08-31 2002-08-21 Use of atazanavir in hiv therapy

Publications (1)

Publication Number Publication Date
HUP0401091A2 true HUP0401091A2 (hu) 2004-08-30

Family

ID=23230468

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401091A HUP0401091A2 (hu) 2001-08-31 2002-08-21 Atazanavir alkalmazása HIV-terápiában

Country Status (28)

Country Link
US (1) US20030045501A1 (hu)
EP (1) EP1420799B1 (hu)
JP (1) JP2005501880A (hu)
KR (1) KR20040029447A (hu)
CN (1) CN1245988C (hu)
AT (1) ATE341332T1 (hu)
AU (1) AU2002332610B2 (hu)
BG (1) BG108585A (hu)
BR (1) BR0211544A (hu)
CA (1) CA2458807A1 (hu)
CZ (1) CZ2004288A3 (hu)
DE (1) DE60215189T2 (hu)
DK (1) DK1420799T3 (hu)
EE (1) EE200400065A (hu)
ES (1) ES2274119T3 (hu)
HK (1) HK1061640A1 (hu)
HR (1) HRP20040181A2 (hu)
HU (1) HUP0401091A2 (hu)
IL (1) IL159849A0 (hu)
IS (1) IS7158A (hu)
MX (1) MXPA04001721A (hu)
NO (1) NO20040803L (hu)
NZ (1) NZ530722A (hu)
PL (1) PL367873A1 (hu)
RU (1) RU2316341C2 (hu)
WO (1) WO2003020206A2 (hu)
YU (1) YU12204A (hu)
ZA (1) ZA200401412B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US20050148523A1 (en) * 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
EP2003120B9 (en) * 2007-06-12 2010-06-02 CoNCERT Pharmaceuticals, Inc. Azapeptide derivatives as HIV protease inhibitors
ES2361796T3 (es) * 2007-06-22 2011-06-22 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
JP2010530890A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
NZ584968A (en) * 2007-10-29 2012-11-30 Cipla Ltd Novel antiretroviral combination comprising ritonavir and atazanavir
CN101249138B (zh) * 2008-03-28 2012-03-21 中国人民解放军军事医学科学院野战输血研究所 一种含五味子乙醇提取物的抗艾滋病药物组合物
CN102905698A (zh) * 2010-04-02 2013-01-30 菲弗科-1有限责任公司 包含ccr5拮抗剂、hiv-1蛋白酶抑制剂和药代动力学增强剂的组合疗法

Also Published As

Publication number Publication date
BR0211544A (pt) 2004-07-13
RU2316341C2 (ru) 2008-02-10
MXPA04001721A (es) 2004-05-31
DE60215189T2 (de) 2007-10-25
EE200400065A (et) 2004-06-15
DE60215189D1 (de) 2006-11-16
HRP20040181A2 (en) 2004-08-31
JP2005501880A (ja) 2005-01-20
CZ2004288A3 (cs) 2004-12-15
NO20040803L (no) 2004-02-24
DK1420799T3 (da) 2007-01-15
CN1547476A (zh) 2004-11-17
ZA200401412B (en) 2005-03-18
ATE341332T1 (de) 2006-10-15
AU2002332610B2 (en) 2007-11-08
IL159849A0 (en) 2004-06-20
KR20040029447A (ko) 2004-04-06
WO2003020206A2 (en) 2003-03-13
US20030045501A1 (en) 2003-03-06
EP1420799A4 (en) 2004-11-24
ES2274119T3 (es) 2007-05-16
EP1420799A2 (en) 2004-05-26
CN1245988C (zh) 2006-03-22
EP1420799B1 (en) 2006-10-04
IS7158A (is) 2004-02-19
HK1061640A1 (en) 2004-09-30
PL367873A1 (en) 2005-03-07
BG108585A (bg) 2005-04-30
WO2003020206A3 (en) 2003-10-02
YU12204A (sh) 2006-08-17
CA2458807A1 (en) 2003-03-13
NZ530722A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
CY1110604T1 (el) Συνδυασμος αναστολεων πρωτεασης που εξαρτωνται απο το κυτοχρωμα ρ450
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
NO20063958L (no) HIV integrase inhibitorer
IL175211A0 (en) Pharmaceutical compositions and kits containing a hepatitis c virus ns3/4a protease inhibitor and cytochrome p450 monooxygenase inhibitor
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
EA200401525A1 (ru) Способы лечения гепатита (варианты )
NO20034094L (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
NO20053455L (no) Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer
HUP0401091A2 (hu) Atazanavir alkalmazása HIV-terápiában
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
TW200738700A (en) HIV integrase inhibitors
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
HUP0203295A2 (hu) Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2004101512A3 (en) Naphthyridine integrase inhibitors
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
EP1696918A4 (en) METHOD FOR THE TREATMENT OF HIV INFECTIONS IN PATIENTS WITH ATAZANAVIR RESISTANCE USING A COMBINATION OF ATAZANAVIR AND ANOTHER PROTEASE INHIBITOR
HUP9904408A2 (hu) Lactobacillus vakcina prosztatagyulladás és jóindulatú prostatahyperplasia kezelésére
NO20050445L (no) Synergistisk interaksjon mellom abacavir og alovudin
DE50112512D1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel
HUP0303423A2 (hu) HIV elleni természetes ellenanyag
HUP0300682A2 (hu) Dalfopristin/kinupristin kombinációit cefpirommal együtt tartalmazó gyógyszerkészítmények